Reona Sakemura Division of Hematology Mayo Clinic Biography Publications Institution JoVE Articles Reona Sakemura My research is focused on adoptive cellular therapy and allogeneic transplantation for hematological malignancies. After completing a fellowship in hematology and medical oncology in Japan, I joined the translational research program of the Nagoya University Graduate School of Medicine, where I trained for three years. My work involved the development of inducible chimeric antigen receptor (CAR) T cell therapy for acute lymphoblastic leukemia. An inducible model could reduce CART cell therapy-related toxicities such as off-target effects. I joined Dr. Kenderian’s laboratory at the Mayo Clinic in April 2017. I have led numerous innovative projects focused on developing CART cell therapies that target the microenvironment of hematological malignancies, non-invasively imaging CART cells with positron emission tomography and a combination of CART cell therapy with small molecule inhibitors. Publications Management of Cytokine Release Syndrome: an Update on Emerging Antigen-specific T Cell Engaging Immunotherapies Immunotherapy. Jul, 2019 | Pubmed ID: 31161844 GM-CSF Inhibition Reduces Cytokine Release Syndrome and Neuroinflammation but Enhances CAR-T Cell Function in Xenografts Blood. Feb, 2019 | Pubmed ID: 30463995 Imagem dinâmica das células T do receptor de antígeno quimérico com [18F]Tetrafluoroborate Positron Emission Tomography/Tomografia Computadorizada Reona Sakemura1,2, Michelle J. Cox1,2, Aditya Bansal3, Claudia Manriquez Roman1,2,4,5, Mehrdad Hefazi1,2, Cynthia J. Vernon3, Dianna L. Glynn3, Mukesh K. Pandey3, Timothy R. DeGrado3, Elizabeth L. Siegler1,2, Saad S. Kenderian1,2,5,6 1T Cell Engineering, Mayo Clinic, 2Division of Hematology, Mayo Clinic, 3Department of Radiology, Mayo Clinic, 4Regenerative Sciences PhD, Mayo Clinic, 5Department of Molecular Medicine, Mayo Clinic, 6Department of Immunology, Mayo Clinic JoVE 62334 Cancer Research Usando CRISPR/Cas9 para knock out GM-CSF em células CAR-T Rosalie M. Sterner1,2, Michelle J. Cox3, Reona Sakemura3, Saad S. Kenderian2,3 1Mayo Clinic Medical Scientist Training Program, Mayo Clinic College of Medicine and Science, 2Department of Immunology, Mayo Clinic, 3Division of Hematology, Mayo Clinic JoVE 59629 Cancer Research
Imagem dinâmica das células T do receptor de antígeno quimérico com [18F]Tetrafluoroborate Positron Emission Tomography/Tomografia Computadorizada Reona Sakemura1,2, Michelle J. Cox1,2, Aditya Bansal3, Claudia Manriquez Roman1,2,4,5, Mehrdad Hefazi1,2, Cynthia J. Vernon3, Dianna L. Glynn3, Mukesh K. Pandey3, Timothy R. DeGrado3, Elizabeth L. Siegler1,2, Saad S. Kenderian1,2,5,6 1T Cell Engineering, Mayo Clinic, 2Division of Hematology, Mayo Clinic, 3Department of Radiology, Mayo Clinic, 4Regenerative Sciences PhD, Mayo Clinic, 5Department of Molecular Medicine, Mayo Clinic, 6Department of Immunology, Mayo Clinic JoVE 62334 Cancer Research
Usando CRISPR/Cas9 para knock out GM-CSF em células CAR-T Rosalie M. Sterner1,2, Michelle J. Cox3, Reona Sakemura3, Saad S. Kenderian2,3 1Mayo Clinic Medical Scientist Training Program, Mayo Clinic College of Medicine and Science, 2Department of Immunology, Mayo Clinic, 3Division of Hematology, Mayo Clinic JoVE 59629 Cancer Research